home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2999.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
51 lines
Document 2999
DOCN M94A2999
TI Are some HIV-related non-Hodgkin's lymphomas curable malignancies?
DT 9412
AU Vaccher E; Tirelli U; Errante D; Serraino D; Tavio M; Spina M; Bernardi
D; Nasti G; Carbone A; Division of Medical Oncology and AIDS, C.R.O.,
Aviano, Italy.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):177 (abstract no. PB0136). Unique
Identifier : AIDSLINE ICA10/94369576
AB OBJECTIVE: The overall outcome of patients with HIV-related
non-Hodgkin's lymphomas (HIV-NHL) is poor because of the adverse
clinico-pathological features and of the underlying HIV infection.
However, the increased experience of physicians using intensive
chemotherapy, has led to an improvement in the prognosis of systemic
HIV-related NHL. Today some patients with AIDS may be expected to
survive for at least 4-5 years, so that it is possible to evaluate the
potential long-term efficacy of the treatment of patients with
aggressive NHL, such as Burkitt's lymphoma, that usually may be
considered curable after two years of lasting complete remission (CR)
after chemotherapy. To evaluate this possibility, we reviewed our
monoinstitutional experience at the Aviano Cancer Institute, Italy, with
emphasis on the clinico-pathological characteristics of a subgroup of 13
patients with long-term survival, observed between April 1985 and
February 1993. METHODS: We have arbitrarily identified two groups of
patients, the first one (group A) including patients with a CR lasting
for at least two years and the other comprising all remaining patients
(group B). RESULTS: Comparing the two groups we found that the 13
patients of group A differed significantly from the other patients in
terms of better CD4+ cell count and performance status (PS) at the time
of diagnosis of NHL, while there was no significant difference in the
histological subtypes. The overall survival of the 73 patients was 8
months. Four prognostic factors influenced survival: younger patients,
those who had a better PS, those with CD4+ cell count > or = 100/mm3 and
patients without B symptoms had a significantly longer survival period.
The median survival in patients of group A was 42 months (range 24-72),
but none of these patients relapsed after up to 6 years of observation.
DISCUSSION AND CONCLUSIONS: A subgroup of patients can be cured from
HIV-related NHL, with some being alive without evidence of disease 3 to
6 years after therapy, and others who died of causes related to
underlying HIV infection, in particular opportunistic infections, but
without relapse of NHL.
DE Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY
Antineoplastic Agents, Combined/*THERAPEUTIC USE Cause of Death
Follow-Up Studies Human Italy Lymphoma, AIDS-Related/*DRUG
THERAPY/MORTALITY Remission Induction Support, Non-U.S. Gov't
Survival Rate MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).